Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus rating of “Buy” from the twenty-five research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $205.83.

A number of brokerages have recently commented on ILMN. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $205.00 price objective (up previously from $200.00) on shares of Illumina in a research report on Wednesday, October 25th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective for the company in a research report on Tuesday, December 5th. Bank of America lifted their price objective on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. BidaskClub downgraded Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $217.50 price objective for the company in a research report on Tuesday, September 19th.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $212.55, for a total transaction of $4,251,000.00. Following the completion of the sale, the director now owns 505,980 shares of the company’s stock, valued at $107,546,049. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 136,421 shares of company stock valued at $28,489,101. 0.89% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Winslow Capital Management LLC purchased a new stake in shares of Illumina in the second quarter worth about $211,584,000. HPM Partners LLC boosted its position in shares of Illumina by 29,103.8% in the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after buying an additional 749,424 shares during the period. Fred Alger Management Inc. boosted its position in shares of Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after buying an additional 548,030 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after buying an additional 527,548 shares during the period. Finally, Capital World Investors boosted its position in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after buying an additional 410,000 shares during the period. 91.75% of the stock is owned by hedge funds and other institutional investors.

Illumina (ILMN) traded up $1.91 during midday trading on Friday, hitting $214.55. The stock had a trading volume of 502,754 shares, compared to its average volume of 951,310. Illumina has a 12 month low of $124.82 and a 12 month high of $230.72. The firm has a market capitalization of $31,270.00, a PE ratio of 62.60, a price-to-earnings-growth ratio of 3.54 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the previous year, the firm posted $0.97 earnings per share. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. analysts forecast that Illumina will post 3.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Receives Average Recommendation of “Buy” from Brokerages” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/illumina-inc-ilmn-receives-average-recommendation-of-buy-from-brokerages/1762235.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.